瓦尔内瓦疫苗
VALN
5.61
-0.30
-5.08%
瓦尔内瓦疫苗
US · VALN
#3677 按市值排名
上市于 2021
5.61
-0.30
-5.08%
实时 - 追踪5344个代码 - 心跳于521秒前
· 2026-10-16 16:04
✦ 量化财务健康度 计算方式说明
偏弱
- 奥特曼 Z 值为-1.14，低于1.8的"危险区"阈值。
- 该模型对工业和制造业公司最为可靠，对银行、保险等金融类公司参考意义较弱。
营收 年度数据，近8年
最近年度同比+3.00%
利润率
- 毛利率
- 38.66%
- 营业利润率
- -46.74%
- 净利率
- -65.95%
关键比率与质量指标
奥特曼 Z 值低于约1.8提示财务困境风险，高于约3.0提示风险较低；该模型对工业和制造业公司最为可靠，对银行等金融类公司参考意义较弱。
利润表
| 项目 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 营收 | 113.04M | 126.20M | 110.32M | 348.09M | 361.30M | 153.71M | 169.58M | 174.66M |
| 毛利润 | 68.59M | 73.42M | 56.02M | 160.17M | 36.86M | 52.84M | 71.04M | 67.52M |
| 销售及管理费用 | 37.71M | 42.54M | 45.80M | 71.25M | 57.58M | 96.55M | 95.11M | 74.68M |
| 研发费用 | 25.29M | 38.02M | 84.45M | 173.28M | 104.92M | 59.89M | 74.14M | 85.30M |
| 营业利润 | 6.27M | -812.00K | -55.12M | -61.35M | -113.44M | -82.11M | -77.77M | -81.63M |
| 税前利润 | 3.35M | -870.00K | -65.30M | -69.98M | -144.82M | -98.63M | -11.49M | -114.12M |
| 税费 | 88.00K | 874.00K | -909.00K | 3.45M | -1.54M | 2.80M | 761.00K | 1.07M |
| 净利润 | 3.26M | -1.74M | -64.39M | -73.43M | -143.28M | -101.43M | -12.25M | -115.19M |
| 基本每股收益 | 0 | 0 | -1 | -2 | -2 | -1 | 0 | -1 |
| 稀释每股收益 | 0.08 | -0.04 | -1.42 | -1.50 | -2.48 | -1.46 | -0.16 | -1.36 |
| 项目 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| 营收 | 49.23M | 48.33M | 29.41M | 47.69M | 30.90M | 34.94M |
| 毛利润 | 26.19M | 24.21M | 5.50M | 11.62M | 4.72M | 1.60M |
| 销售及管理费用 | 19.36M | 19.99M | 18.80M | 16.54M | 15.14M | 13.77M |
| 研发费用 | 14.95M | 17.49M | 27.29M | 25.57M | 15.22M | 15.02M |
| 营业利润 | -5.96M | -10.64M | -37.35M | -27.69M | -23.70M | -26.17M |
| 税前利润 | -7.76M | -11.81M | -43.47M | -51.08M | -31.25M | -31.77M |
| 税费 | 1.47M | -223.00K | 882.00K | -1.06M | 824.00K | -566.00K |
| 净利润 | -9.23M | -11.59M | -44.36M | -50.02M | -32.07M | -31.20M |
| 基本每股收益 | 0 | 0 | -1 | -1 | 0 | 0 |
| 稀释每股收益 | -0.12 | -0.14 | -0.52 | -0.58 | -0.36 | -0.34 |
资产负债表
| 项目 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 流动资产总额 | 125.97M | 129.16M | 308.43M | 585.83M | 424.66M | 262.82M | 299.01M | 222.54M |
| 现金及短期投资 | 77.09M | 64.44M | 204.39M | 346.64M | 286.53M | 126.08M | 168.27M | 109.65M |
| 存货 | 22.73M | 25.77M | 26.93M | 124.10M | 35.10M | 44.47M | 53.66M | 50.23M |
| 总资产 | 229.91M | 264.72M | 449.16M | 817.35M | 621.34M | 460.06M | 500.03M | 398.84M |
| 流动负债总额 | 42.94M | 41.30M | 175.87M | 368.98M | 277.39M | 158.86M | 114.58M | 93.33M |
| 短期负债 | 17.53M | 4.31M | 9.68M | 10.24M | 36.99M | 46.96M | 23.36M | 20.64M |
| 长期负债 | 14.27M | 24.32M | 46.38M | 50.73M | 87.23M | 132.77M | 166.52M | 161.26M |
| 总负债 | 86,721,000.00 | 129,570,000.00 | 371,742,000.00 | 646,771,000.00 | 401,547,000.00 | 331,815,000.00 | 318,779,000.00 | 292,668,000.00 |
| 股东权益总额 | 143.19M | 135.15M | 77.42M | 170.58M | 219.80M | 128.25M | 181.25M | 106.17M |
| 留存收益 | -168.17M | -169.16M | -233.55M | -306.97M | -450.25M | -551.68M | -563.93M | -679.12M |
| 项目 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| 流动资产总额 | 287.05M | 284.72M | 268.33M | 222.54M | 201.44M | 222.88M |
| 现金及短期投资 | 152.99M | 161.31M | 143.46M | 109.65M | 105.27M | 121.53M |
| 存货 | 61.68M | 61.73M | 64.29M | 50.23M | 50.58M | 48.16M |
| 总资产 | 482.24M | 472.63M | 448.23M | 398.84M | 372.01M | 388.28M |
| 流动负债总额 | 106.20M | 125.66M | 150.48M | 93.33M | 94.22M | 103.33M |
| 短期负债 | 22.40M | 48.67M | 61.51M | 20.64M | 21.01M | 21.16M |
| 长期负债 | 161.48M | 122.36M | 108.89M | 161.26M | 164.06M | 165.63M |
| 总负债 | 306,989,000.00 | 286,193,000.00 | 297,752,000.00 | 292,668,000.00 | 295,314,000.00 | 307,155,000.00 |
| 股东权益总额 | 175.25M | 186.43M | 150.48M | 106.17M | 76.70M | 81.12M |
| 留存收益 | -573.16M | -584.75M | -629.10M | -679.12M | -711.19M | -742.40M |
现金流量表
| 项目 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 经营活动现金流 | 16.31M | 5.53M | 137.74M | 76.90M | -245.34M | -202.74M | -67.22M | -52.89M |
| 折旧与摊销 | 6.83M | 8.53M | 9.80M | 14.28M | 21.04M | 17.58M | 19.59M | 21.75M |
| 自由现金流 | 13.14M | -5.36M | 118.27M | -16.27M | -274.67M | -217.06M | -83.66M | -57.38M |
| 已派股息 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 股票回购/发行 | 49.26M | -2.46M | 290.00K | 166.82M | 189.84M | -240.00K | 57.14M | 30.00M |
| 期末现金余额 | 77.08M | 64.44M | 204.44M | 346.64M | 286.53M | 126.08M | 168.27M | 109.65M |
| 项目 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| 经营活动现金流 | -8.15M | -2.80M | -17.44M | -24.51M | -313.00K | -13.43M |
| 折旧与摊销 | -- | -- | -- | -- | -- | -- |
| 自由现金流 | -9.62M | -4.05M | -18.11M | -25.59M | -565.00K | -13.77M |
| 已派股息 | 0 | 0 | 0 | 0 | 0 | 0 |
| 股票回购/发行 | 0 | 20.14M | 6.11M | 3.76M | 920.00K | 34.38M |
| 期末现金余额 | 152.99M | 161.31M | 143.46M | 109.65M | 105.27M | 121.53M |
回报与效率指标
| 项目 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 净资产收益率i | 2.77 | -1.25 | -60.58 | -59.21 | -73.41 | -58.29 | -7.91 | -80.16 |
| 总资产收益率i | 1.56 | -0.71 | -18.04 | -11.59 | -19.92 | -18.76 | -2.55 | -25.63 |
| 投入资本回报率i | 3.72 | -0.03 | -26.74 | -26.12 | -37.93 | -23.92 | 1.08 | -23.94 |
| 5年平均净资产收益率i | -16.86 | -13.20 | -22.25 | -26.04 | -38.34 | -50.55 | -51.88 | -55.79 |
| 息税前利润率i | 6.32 | 1.40 | -49.46 | -15.23 | -34.81 | -48.99 | 7.37 | -41.35 |
| 自由现金流/营收i | 11.62 | -- | 107.20 | -- | -- | -- | -- | -- |
| 流动比率i | 2.93 | 3.13 | 1.75 | 1.59 | 1.53 | 1.65 | 2.61 | 2.38 |
| 速动比率i | 2.06 | 2.14 | 1.27 | 1.06 | 1.12 | 1.06 | 1.78 | 1.47 |
| 资产负债率i | 25.05 | 32.19 | 23.48 | 14.03 | 24.52 | 45.39 | 43.26 | 51.96 |
| 长期负债权益比i | 27.98 | 59.86 | 123.69 | 61.21 | 52.50 | 126.21 | 106.46 | 175.76 |
| 利息保障倍数i | 1.88 | 0.67 | -5.08 | -3.13 | -6.60 | -3.23 | 0.52 | -1.72 |
| 营收复合年增长率(3年)i | 12.99 | 10.29 | 1.57 | 45.49 | 42.00 | 11.69 | -21.31 | -21.52 |
| 净利润复合年增长率(3年)i | -- | -- | -- | -- | -- | -- | -- | -- |
| 自由现金流复合年增长率(3年)i | -- | -- | 137.83 | -- | -- | -- | -- | -- |
| 项目 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| 净资产收益率i | -44.11 | -38.01 | -55.53 | -80.16 | -109.57 | -117.85 |
| 总资产收益率i | -16.32 | -14.28 | -21.18 | -25.63 | -32.32 | -36.62 |
| 投入资本回报率i | -16.55 | -13.51 | -22.67 | -23.94 | -34.05 | -39.68 |
| 5年平均净资产收益率i | -- | -- | -- | -- | -- | -- |
| 息税前利润率i | -29.69 | -21.03 | -39.94 | -41.35 | -61.79 | -81.83 |
| 自由现金流/营收i | -- | -- | -- | -- | -- | -- |
| 流动比率i | 2.70 | 2.27 | 1.78 | 2.38 | 2.14 | 2.16 |
| 速动比率i | 1.76 | 1.48 | 1.09 | 1.47 | 1.22 | 1.33 |
| 资产负债率i | 43.78 | 41.67 | 43.69 | 51.96 | 56.32 | 54.14 |
| 长期负债权益比i | 107.70 | 79.52 | 89.27 | 175.76 | 245.76 | 233.08 |
| 利息保障倍数i | -2.41 | -1.75 | -3.05 | -1.72 | -2.36 | -2.88 |
| 营收复合年增长率(3年)i | -- | -- | -- | -- | -- | -- |
| 净利润复合年增长率(3年)i | -- | -- | -- | -- | -- | -- |
| 自由现金流复合年增长率(3年)i | -- | -- | -- | -- | -- | -- |
✦ 量化营收集中度 计算方式说明
主业突出，长尾分散
- 在披露的10个业务分部中，IXIARO®是最大的一项，占营收的56.35%。
- 紧随其后的DUKORAL®占比18.27%，说明主业仍最重要，但并非全部。
营收构成 最近报告期
业务分部
IXIARO®56.35%
DUKORAL®18.27%
Third party products10.97%
R&D work and additional support services5.72%
IXCHIQ®4.82%
Milestone payment - licenses1.96%
Royalties received1.22%
Other non - International Financial Reporting Standards (IFRS) 15 revenue0.37%
Revenues from shipping and handling0.28%
地区分部
United States30.69%
Canada17.25%
Germany10.00%
France8.40%
Nordics7.96%
Other Europe7.95%
United Kingdom7.24%
Austria5.42%
Rest of world5.09%
报价时间 2026-10-16 16:04:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
瓦尔内瓦疫苗 讨论区 0 条评论